Diagnostic value of p53 immunohistochemistry in Barrett's esophagus: An endoscopic study

Summary The aim of this study was to establish the diagnostic utility of p53 immunohistochemistry in Barrett's esophagus. Three pathologists reviewed endoscopic biopsy specimens and one surgical specimen derived from 102 subjects in a prospective follow‐up series. Dysplasia was graded as negative, indefinite, low grade and high grade. p53 staining was assessed as negative, weak or patchy and strong. Kappa coefficients for interobserver agreement for the three combinations of observer pairs were moderate to substantial (0.48, 0.55 and 0.68) for dysplasia and substantial to near perfect (0.77, 0.82 and 0.89) for p53 immunostaining. In the consensus grading achieved for dysplasia, strong p53 staining was recorded in 0/79 samples that were negative or indefinite for dysplasia, 5/15 (33%) examines of low grade dysplasia and 7/8 (87%) examples of high grade dysplasia. Non‐dysplastic p53 positive glands were seen in specimens from two subjects harbouring dysplasia or cancer elsewhere. Two p53 positive specimens were, upon review and discussion, re‐assigned from low‐ to high‐grade dysplasia. It is concluded that p53 immunohistochemistry facilitates the interpretation of Barrett's epithelium but need only be employed to confirm a suspected diagnosis of dysplasia and assist with the distinction between low‐ and high‐grade dysplasia.

[1]  J. Roth,et al.  Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. , 1996, The Journal of thoracic and cardiovascular surgery.

[2]  J. Sloan,et al.  Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma. , 1995, Cancer research.

[3]  J. Field,et al.  Frequent loss of heterozygosity on chromosome 17 at 17q11.2-q12 in Barrett's adenocarcinoma. , 1995, British Journal of Cancer.

[4]  J. Goldblum,et al.  p53 immunoreactivity in Barrett's metaplasia, dysplasia, and carcinoma. , 1994, The Journal of thoracic and cardiovascular surgery.

[5]  G. Thomas,et al.  TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. , 1994, Gastroenterology.

[6]  J. Linehan,et al.  p53 expression in Barrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO‐7 , 1994, The Journal of pathology.

[7]  Carissa A. Sanchez,et al.  p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. , 1994, Gastroenterology.

[8]  N. Shepherd,et al.  Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence. , 1994, Gut.

[9]  D. Quinlan,et al.  Potential application of p53 as an intermediate biomarker in Barrett's esophagus. , 1994, The Annals of thoracic surgery.

[10]  D. Beer,et al.  Intestinal differentiation and p53 gene alterations in barrett's esophagus and esophageal adenocarcinoma , 1994, International journal of cancer.

[11]  R. Lebovitz,et al.  p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. , 1993, Gastroenterology.

[12]  Patricia L. Blount,et al.  Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[13]  T. McDaniel,et al.  Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas. , 1993, Cancer research.

[14]  J. Fléjou,et al.  Overexpression of p53 protein in Barrett's syndrome with malignant transformation. , 1993, Journal of clinical pathology.

[15]  P. Blount,et al.  Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. , 1992, Gastroenterology.

[16]  N. Walker,et al.  Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. , 1991, Gut.

[17]  Carissa A. Sanchez,et al.  17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. , 1991, Cancer research.

[18]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[19]  D. Lane,et al.  Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. , 1990, The EMBO journal.

[20]  J. G. van den Tweel,et al.  Barrett's esophagus: development of dysplasia and adenocarcinoma. , 1989, Gastroenterology.

[21]  J. Mayberry,et al.  Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus , 1988, The British journal of surgery.

[22]  A. Levine,et al.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life , 1988, Molecular and cellular biology.

[23]  G Van Belle,et al.  Observer variation in the diagnosis of dysplasia in Barrett's esophagus. , 1988, Human pathology.

[24]  W S Payne,et al.  The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. , 1985, The New England journal of medicine.

[25]  J. Boitnott,et al.  The spectrum of carcinoma arising in Barrett's esophagus: A clinicopathologic study of 26 patients , 1984, The American journal of surgical pathology.

[26]  D. Skinner,et al.  Barrett's Esophagus: Comparison of Benign and Malignant Cases , 1983, Annals of surgery.

[27]  J. Freston,et al.  Malignant transformation of esophageal columnar epithelium , 1978, Cancer.

[28]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[29]  M. Savary,et al.  Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett's esophagus with 12 adenocarcinomas. , 1975, The Journal of thoracic and cardiovascular surgery.

[30]  Jacob Cohen,et al.  Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit. , 1968 .

[31]  Jacob Cohen.  A Coefficient of Agreement for Nominal Scales , 1960 .

[32]  H. Tilanus,et al.  Prognostic value of p53 in Barrett's oesophagus. , 1995, European journal of gastroenterology & hepatology.

[33]  J. Roth,et al.  Clinical implications of p53 gene mutation in the progression of Barrett's epithelium to invasive esophageal cancer. , 1994, American journal of surgery.

[34]  P. Blount,et al.  Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. , 1992, Gastroenterology.

[35]  N. Altorki,et al.  High-grade dysplasia in the columnar-lined esophagus. , 1991, American journal of surgery.

[36]  N R BARRETT,et al.  The lower esophagus lined by columnar epithelium. , 1957, Surgery.